RxDoctor Payments Data

David Rubin, MD

Cardiovascular Disease · Bel Air, MDNPI 1598759326

Payments from drug & device makers

$9,210in general payments, 2019–2025

Across 566 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$813
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$798
  • Amgen$712
  • Novartis$651
  • AOP Health US, LLC$560
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,181100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,210 in reported general payments places this provider in the 75th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$416,014
Medicare patients
2,681
Services billed
10,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban514$669,417
XareltoRivaroxaban276$388,897
MultaqDronedarone Hcl83$134,038
Repatha SureclickEvolocumab104$125,693
Rosuvastatin Calcium1,510$30,262
BrilintaTicagrelor35$30,098
Ezetimibe741$29,289
Repatha SyringeEvolocumab22$23,431
JardianceEmpagliflozin22$22,291
Metoprolol Succinate793$14,460
Digoxin405$11,559
NexletolBempedoic Acid12$10,659
Atorvastatin Calcium713$10,299
Olmesartan Medoxomil305$8,078
ClopidogrelClopidogrel Bisulfate373$5,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$813$669,417514 claims
Johnson & JohnsonXarelto$553$388,897276 claims
Sanofi-aventis U.S. LLCMultaq$166$134,03883 claims
AstraZenecaBrilinta$477$30,09835 claims
Boehringer IngelheimJardiance$424$22,29122 claims
Esperion Therapeutics, Inc.Nexletol$80$10,65912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →